combination therapy with ceftazidim and amikacin versus Imipenem monotherapy for empirical treatment of febrile neutropenic cancer patients.
Not Applicable
- Conditions
- eutropenia.Agranulocytosis
- Registration Number
- IRCT2012121511756N1
- Lead Sponsor
- Arak University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 122
Inclusion Criteria
patients aged more than 18 years with cancer; recent chemotherapy; oral temperature more than 38.3°c or more than 38 °c for 1 hour and neutrophil lower than 1500/micro liter.
Exclusion criteria: pregnancy and breast feeding; use of antibiotic for at least 3 days before randomization; CNS infection; blastic crisis;coma; septic shock and definite origin for fever.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Fever. Timepoint: daily for 3 days. Method of measurement: centigrade-termometer.;Culture. Timepoint: day 1-day 3. Method of measurement: colony/mm3-culture medium.
- Secondary Outcome Measures
Name Time Method Convulsion. Timepoint: daily during treatment period. Method of measurement: history.;Renal failure. Timepoint: daily during treatment period. Method of measurement: milligram/deciliter-creatinin measurement.